Jack Anders - 18 Dec 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: RVMD
Reported as of: 18 Dec 2023
Net transaction value: -$45,976
SEC form: 4
Accepted by SEC: 20 Dec 2023, 17:10:14 UTC
Prior SEC filing: 23 Oct 2023
Next SEC filing: 05 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 20 Dec 2023.

Key facts

This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Dec 2023, 17:10.

Change

Previous filing in this sequence was filed on 23 Oct 2023.
Current net transaction value: -$45,976.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $45,976
Shares: -1,775
Change %: -2.3%
Price: $25.90
Shares after: 76,416
Date: 18 Dec 2023
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

Footnote F2

Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

Footnote F3

This transaction was executed in multiple trades in prices ranging from $25.9017 to $25.9385, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

Includes 37,326 RSUs.